

1 **Feasibility of an interprofessional collaborative osteoporosis screening programme in**
2 **Malaysia**

3

4 **Abstract**

5 Background: Population screening for osteoporosis using bone mineral density scan is not
6 feasible in Malaysia as this test is costly. Hence, there is a need to develop a more efficient
7 method to screen for osteoporosis.

8 Objectives: To determine the feasibility of an interprofessional collaborative osteoporosis
9 screening programme (IPC-OSP)

10 Methods: Postmenopausal women aged ≥ 50 years, who had not been diagnosed with
11 osteoporosis were recruited from a primary care clinic from June-August 2014. Patients were
12 assessed for their osteoporosis risk and were counselled on prevention methods. Patients at risk
13 were referred to the doctor with a recommendation for a bone mineral density (BMD) scan.

14 Results: Fifty out of 55 patients were recruited [response rate=90.9%]. A total 26/50(52.0%)
15 went for a BMD scan, none were osteoporotic, 17/50(34%) were osteopenic, 2/50(4.0%), were
16 started on osteoporosis medications and 14/50(28%) modified their lifestyle to improve bone
17 health or started on calcium supplements. Osteoporosis knowledge significantly increased from
18 baseline to month two (46.3 ± 21.4 vs 79.1 ± 14.3 , $p < 0.001$). Patients had a satisfaction score of
19 89.8 ± 12.4 . Follow-up rates were 83.9% and 100% at months 1 (BMD appointment) and 2 (phone
20 follow up), respectively. The intervention was successfully coordinated. Data entry was
21 determined to be viable based on the researchers' experience.

22 Conclusion: The IPC-OSP was found to be feasible in Malaysia.

23 Impact on practice:

- 24 - An interprofessional collaborative osteoporosis screening programme (IPC-OSP) was
25 developed in Malaysia as it was not cost effective to perform population screening for
26 osteoporosis using the bone mineral density scan
- 27 - Interprofessional collaboration in osteoporosis screening is important as collaborative
28 initiatives have demonstrated better patient outcomes, reduced cost and improved
29 working relationships among health disciplines.
- 30 - An interprofessional collaborative osteoporosis screening program by doctors and
31 pharmacists was feasible when implemented in one primary care clinic in Malaysia.
- 32 - However, the role of nurses was unclear as nurses may require additional training on how
33 to identify women who may be at risk for osteoporosis.

34

35

36

37 **Introduction**

38 Approximately 20% of women who had an osteoporosis-related fracture received either a bone
39 mineral density (BMD) scan; or were prescribed medications to treat osteoporosis within the
40 period of six months after the fracture has occurred [1]. An interprofessional collaborative
41 osteoporosis screening programme (IPC-OSP) was developed in Malaysia as it was not cost
42 effective to perform population screening for osteoporosis using the bone mineral density scan.
43 However, before an intervention can be implemented in clinical practice, the feasibility of the
44 intervention should be determined.

45
46 **Aim of the study**

47 To determine the feasibility of an interprofessional collaborative osteoporosis screening
48 programme (IPC-OSP) in a primary care clinic in Malaysia.

49
50 **Ethics approval**

51 Ethical approval from the University Malaya Medical Centre Ethics Committee was obtained
52 prior to the study (ref no. 920.26).

53
54 **Methods**

55 **Setting and participants**

56 Community-dwelling postmenopausal women aged ≥ 50 years old who had not been diagnosed
57 with osteopenia/osteoporosis were recruited at a primary care clinic in Kuala Lumpur from June
58 to August 2014. Participants with a history of metabolic disease, presence of bone metastasis,
59 significant renal impairment, previous bilateral oophorectomy, history of hip fracture or prior use
60 of bisphosphonates were excluded.

61
62 **Primary and secondary outcomes**

63 The typology developed by Tickle-Dengen (2013) was used to categorize the primary and
64 secondary outcomes. Four aspects were assessed: scientific, process, resources and management
65 outcomes[2, 3].

66

67 **Primary outcomes**

68 **Scientific assessment**

69 Our primary outcome was to measure the proportion of patients who went for a BMD scan.

70

71 **Secondary outcomes**

72 **Scientific assessments**

73 Five secondary scientific outcomes were measured: the proportion of patients 1) diagnosed with
74 osteoporosis/osteopenia, 2) started on osteoporosis medications, 3) who modified their lifestyle
75 to improve bone health (by taking calcium supplements, increasing their dietary calcium or
76 performing weight-bearing exercises), patients' 4) who had an increase in osteoporosis
77 knowledge and 5) who were satisfied with the IPC-OSP.

78

79 Patients' osteoporosis knowledge was measured pre- and post-intervention. Patients' satisfaction
80 towards the IPC-OSP was measured at the end of the feasibility study.

81

82 **Process assessment**

83 The intervention's processes: such as response rates, follow-up rates, suitability of the
84 inclusion/exclusion criteria, suitability of data collection methods, amount of patients' time to
85 complete the intervention and capacity to complete data collection procedures were assessed.

86

87 **Resource assessment**

88 The resources assessed were the coordination of intervention between nurses, pharmacists,
89 patients and doctors, and time to conduct the intervention at each stage. Other resources assessed
90 were the physical conditions (space and comfort), whether there was sufficient equipment
91 available and documentation of research forms.

92

93

94 **Management assessment**

95 This was assessed by determining the accuracy of data entry and adherence to the ethics of
96 research. The researcher's experience (as a clinical pharmacist who was familiar with the

97 capacity and workflow of the clinic) was used to assess the process, resource and management
98 assessments.

99

100 **Instruments used**

101 **Osteoporosis Self-Assessment Tool for Asians (OSTA)**

102 The validated OSTA was used to screen a patient's risk for osteoporosis [4]. Patients were
103 classified as low, moderate or high risk, based on their weight (in kilograms) deducted from age
104 (in years) and multiplied by -0.2 [4].

105

106 **Fracture Risk Assessment tool (FRAX)**

107 The Singapore FRAX model [5] was used to provide additional information regarding patient's
108 fracture risk to aid the doctor in deciding if a BMD scan was needed as the Malaysian FRAX
109 model was not developed when our study was conducted [5].

110

111 **Osteoporosis Prevention and Awareness tool (OPAAT)**

112 The validated OPAAT [6] was used to assess patients' osteoporosis knowledge. It consists of 30
113 items categorized into three domains: osteoporosis in general, consequences of untreated
114 osteoporosis and osteoporosis prevention. Response options were true, false, don't know. A
115 score of one was given for a correct response and zero for an incorrect or do not know response.
116 A higher score indicates better knowledge.

117

118 **Satisfaction Questionnaire for Osteoporosis Prevention (SQOP).**

119 The validated SQOP [7] was used to assess patients' satisfaction towards the IPC-OSP. It
120 consists of 23 questions with a five-point Likert-type response.. Responses were categorized into
121 six domains: outcomes/efficacy, accessibility/convenience, technical quality, interpersonal
122 relationship, finance and continuity. A higher score indicates higher satisfaction.

123


124

125 **The Interprofessional collaborative osteoporosis screening programme (IPC-OSP)**

126 This IPC-OSP was developed from a previous qualitative study which explored the barriers and
127 facilitators regarding an osteoporosis screening programme[8]. The behavioural change wheel

128 was used to analyse this data to ensure that the intervention was acceptable and sustainable[9].
129 Patients' osteoporosis risk was assessed using the OSTA. The FRAX was used to provide
130 additional information regarding the patient's fracture risk. Patients were referred for a BMD
131 scan (if required) and received counselling regarding osteoporosis (Figure 1).
132

Figure 1: Flow chart on the interprofessional collaborative osteoporosis screening programme (IPC-OSP)



134 **Data Analysis**


135 All data was entered into the IBM® SPSS® version 20 (IBM Corporation, Armonk, NY, US).
136 Non-parametric tests were used since data obtained were not normally distributed. Categorical
137 variables were presented as proportion. Continuous variables were presented as median and
138 interquartile range. McNemar’s test was used to examine the pre and post scores of the
139 individual items in the OPAAT. A p-value <0.05 was considered as statistically significant.

141 **Results**

142 A total of 50/55 patients agreed to participate (response rate= 90.9%). A total of 36/50(72%)
143 patients were referred for a BMD scan, of which only 28/36(77.8%) recommendations were
144 accepted by the doctor. additionally, 3 scans were ordered without the pharmacist’s
145 recommendation, as these scans were provided “free of charge”. A total to 31/36 (86.1%) BMD
146 scans were ordered. Reasons provided by the doctors on why BMD scans were not ordered were:
147 3/36(8.3%) patients’ x-ray results were normal; 1/36(2.8%) doctor said that there were more
148 urgent diseases to treat such as heart, endocrine or eye conditions; 1/36(2.8%) patient’s blood
149 calcium levels were normal; 1/36(2.8%) patient was “too young”; 1/36(2.8%) patient’s FRAX
150 fracture risk was considered too low (11% major osteoporosis fracture and 2.2% for hip
151 fracture), and 1/36(2.8%) would be exposed to too much radiation as she had another
152 appointment for a computed tomography (CT) scan. Ultimately, 26/31(83.9%) went for a BMD
153 scan [Figure 2].

154
155
156
157
158
159
160
161
162
163
164

Figure 2: Results of the feasibility study



166 Seventeen out of the 26 patients who went for the BMD scan (65.4%) had osteopenia whilst
167 none had osteoporosis; of which 2/26(7.7%) patients were started on strontium. Among those
168 patients who had a normal BMD scan or osteopenia (n=26), 11 (42.3%) were started on calcium
169 supplements and 3/26 (11.5%) modified their lifestyle to improve bone health (Figure 2).

170
171
172 Only 46/50 patients answered the OPAAT at baseline and one month later (response
173 rate=92.0%). All three domains showed an increase in osteoporosis knowledge: osteoporosis in
174 general (44.7±28.0 to 73.5±26.0), consequences of untreated osteoporosis (50.8±26.9 to
175 93.9±11.8) and prevention of osteoporosis (46.0±25.1 to 79.7±16.2). Overall, knowledge
176 increased from 46.3±21.4 to 79.1±14.3, $p < 0.001$. Knowledge increased in 27/30(90.0%) items.
177 One month later, patients' satisfaction score was 89.8±12.4.

178
179 Based on the response rate of 90.9% we found the inclusion criteria to be suitable. The follow-up
180 rate was 26/31(83.9%) during the first follow-up and 26/26(100%) for the second follow-up.

181
182 **Resource assessment**

183 The pharmacist initially found it difficult to communicate her recommendations and procedures
184 to the doctor. In order to resolve this, the pharmacist conducted individual briefing sessions with
185 the doctors.

186
187 The pharmacist found that the risk assessment, counselling and administration of the OPAAT
188 approximately 30 minutes for each patient. The time allocated was sufficient as patients usually
189 had to wait at least 30 minutes before being called to see the doctor. For the first follow-up
190 session, the administration of the OPAAT, SQOP and information on the BMD results took
191 approximately 15-30 minutes depending on the number of questions the patients had. The second
192 follow-up needed about five minutes.

193
194 Documentation was successful. The forms used by the pharmacists to make recommendations
195 were documented into the patients' medical record. Equipment to measure BMD, height and
196 weight were available throughout the intervention.

197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226

Management assessment

The pharmacist was able to document all data and outcomes needed into SPSS daily. There were also no problems with managing the procedures based on the ethics application.

Discussion

The current workflow was feasible, as both primary and secondary outcomes could be assessed. Our results concurred with previous osteoporosis screening programmes which showed an increase in BMD scans ordered, and initiation of calcium supplements and/or treatment [10].

Initially, the pharmacist had difficulty conveying recommendations to the doctor, and the nurses had difficulty screening for osteoporosis patients. Hence, modifications were made. The pharmacist screened for potential patients herself and this improved the feasibility of the IPC-OSP.

The satisfaction score of the patients were 89.8 ± 12.4 . This score was similar to the score achieved by the intervention group of the SQOP validation study which was 87.9 ± 6.0 . Based on this previous study the cut-off score was defined as 61.0 as the control group in this study achieved a satisfaction score of 61.9 ± 8.8 [7].

Following the process assessments of the IPC-OSP, modifications were made to the data collection method. Initially, nurses were asked to refer potential patients to the pharmacists. This method was inefficient as nurses did not know how to screen patients as they were not trained to screen patients for osteoporosis. The pharmacist then screened for potential patients herself. Our findings were similar to a study in the United States, which found that the osteoporosis screening program performed better when it was conducted by a clinical-pharmacist , as opposed to a registered-nursed[11]. A training session pertaining to the IPC-OSP should be conducted for nurses to address this concern.

227 A limitation of this study was that the sample size used was small and results were not
228 generalisable. However, the aim of this study was not to assess the effectiveness of the
229 intervention. Therefore, we achieved the aim of our study, which was to assess the feasibility of
230 the developed interprofessional collaborative osteoporosis screening programme. A further
231 limitation of this study was the exclusion of men. It is possible that different psychological
232 factors are related to the screening of osteoporosis in men, which need to be explored further.

233
234 The strength of this study was that the IPC-OSP was designed specifically for this setting
235 following a qualitative study [8]. It was then supported by the use of the behavioural change
236 wheel to ensure that the underlying psychological reason to conducting an osteoporosis screening
237 programme was addressed [9]. Additionally, the instruments used (i.e. the OPAAT and the
238 SQOP) were specifically developed and validated for this intervention [6, 7]. Furthermore, the
239 IPC-OSP was coordinated by a pharmacist. The inclusion of pharmacists into healthcare delivery
240 teams in literature have noted improved health outcomes in osteoporosis [12].

241

242 **Conclusion**

243 The IPC-OSP was found to be feasible when assessed in a primary care setting in Malaysia.
244 However, a feasibility study does not assess the effectiveness of the IPC-OSP. A randomized
245 controlled trial would be needed to determine if the IPC-OSP would improve patient outcomes
246 such as reducing the number of osteoporotic-related fractures.

247

248

249 **Conflicts of interest:** Li Shean Toh, Pauline Siew Mei Lai, Bee Yean Low, Kok Thong Wong,
250 and Claire Anderson declare that they have no conflict of interest.

251

252 **Funding:** Ministry of Science, Technology and Innovation (MOSTI) fund (06-02-12-SF0183).

253

254

255

256

257

258 **References**

- 259 1. Cosman F, Lindsay R, LeBoff MS, Jan de Beur S, Tanner B. National Osteoporosis Foundation.
260 Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis
261 Foundation; 2014.
- 262 2. Tickle-Degnen L. Nuts and bolts of conducting feasibility studies. *The American Journal of*
263 *Occupational Therapy*. 2013(67):171-6. doi:10.5014/ajot.2013.006270.
- 264 3. Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP et al. A tutorial on pilot studies: the what, why and
265 how. *BMC Medical Research Methodology*. 2010;10(1):1. doi:10.1186/1471-2288-10-1.
- 266 4. Koh LKH, Sedrine WB, Torralba TP, Kung AW, Fujiwara S, Chan SP et al. A simple tool to identify Asian
267 women at increased risk of osteoporosis. *Osteoporosis international*. 2001;12:699-705.
- 268 5. Kanis JA. FRAX WHO Fracture Risk Assessment Tool. World Health Organization Collaborating Centre
269 for Metabolic Bone Diseases, University of Sheffield, UK. 2014. <http://www.shef.ac.uk/FRAX/>. Accessed
270 22 December 2014.
- 271 6. Toh LS, Lai PS, Wu DB, Wong KT, Low BY, Anderson C. The Development and Validation of the
272 Osteoporosis Prevention and Awareness Tool (OPAAT) in Malaysia. *PLoS One*. 2015;10(5):e0124553.
273 doi:10.1371/journal.pone.0124553.
- 274 7. Toh LS, Lai PSM, Wong KT, Tan ATB, Low BY, Anderson C et al. The development and validation of the
275 Satisfaction Questionnaire for Osteoporosis Prevention in Malaysia. *Patient Preference and Adherence*.
276 2014;8:1365-81. doi:10.2147/ppa.s65718.
- 277 8. Toh LS, Lai PSM, Wong KT, Low BY, Anderson C. What are the barriers encountered while screening
278 for osteoporosis in a government university hospital primary care setting? Preliminary results of a
279 qualitative study on Malaysian nurses views. *Osteoporosis international*. 2012;23(Suppl 7):S777.
- 280 9. Toh LS, Lai PSM, Low BY, Wong KT, Anderson C. The development of a pharmacist-led osteoporosis
281 screening intervention using the behavioural change wheel. *International Journal of Pharmacy Practice*.
282 2016:30.
- 283 10. Elias MN, Burden AM, Cadarette SM. The impact of pharmacist interventions on osteoporosis
284 management: a systematic review. *Osteoporosis international*. 2011;22(10):2587-96.
285 doi:10.1007/s00198-011-1661-7.
- 286 11. Heilmann RMF, Friesleben CR, Billups SJ. Impact of a pharmacist-directed intervention in
287 postmenopausal women after fracture. *American Journal of Health-System Pharmacy*. 2012;69(6):504-9.
288 doi:10.2146/ajhp110309.
- 289 12. Yuksel N, Majumdar SR, Biggs C, Tsuyuki RT. Community pharmacist-initiated screening program for
290 osteoporosis: randomized controlled trial. *Osteoporosis international*. 2010;21(3):391-8.
291 doi:10.1007/s00198-009-0977-z.

292